Development of a topical protein therapeutic for human papillomavirus and associated cancers

BioDrugs

Volumn 20, Issue 4, 2006, Pages 209-218

  Green, Katie L ^a   Gaston, Kevin ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; PROTEIN E6; PROTEIN E7; PROTEIN VP22; RECOMBINANT VACCINE; VIRUS VECTOR;

CELL PROLIFERATION; CONDYLOMA; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VIRUS CELL TRANSFORMATION; WART VIRUS;

ADMINISTRATION, TOPICAL; CELL TRANSFORMATION, VIRAL; DNA-BINDING PROTEINS; DRUG DESIGN; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT PROTEINS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 33646676078     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620040-00002     Document Type: Review

References (142)

1. de Villiers EM. Papillomavirus and HPV typing. Clin Dermatol 1997; 15: 199-206
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50
3. Gissmann L, de Villiers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer 1982; 29: 143-6
4. Cates W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26 (4 Suppl.): S2-7
5. Fox PA, Tung MY. Human papillomavirus: burden of illness and treatment cost considerations. Am J Clin Dermatol 2005; 6: 365-81
6. Andrews SE. Laser ablation of recurrent laryngeal papillomas in children. AORN J 1995; 61: 532-40, 543-4
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9
8. Dell G, Gaston K. Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci 2001; 58: 1923-42
9. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
10. van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000; 36: 2177-88
11. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8
12. Kitchener HC. Gynaecological cancer. Postgrad Med J 1999; 75: 332-8
13. Jones RW, Park JS, McLean MR, et al. Human papillomavirus in women with vulvar intraepithelial neoplasia III. J Reprod Med 1990; 35: 1124-6
14. Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 2001; 22: 393-402
15. Basta A, Adamek K, Pitynski K. Intraepithelial neoplasia and early stage vulvar cancer: epidemiological, clinical and virological observations. Eur J Gynaecol Oncol 1999; 20: 111-4
16. Herod JJ, Shafi MI, Rollason TP, et al. Vulvar intraepithelial neoplasia with superficially invasive carcinoma of the vulva. Br J Obstet Gynaecol 1996; 103: 453-6
17. Schwartz SR, Yueh B, McDougall JK, et al. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001; 125: 1-9
18. Balaram P, Nalinakumari KR, Abraham E, et al. Human papillomaviruses in 91 oral cancers from Indian betel quid chewers: high prevalence and multiplicity of infections. Int J Cancer 1995; 61: 450-4
19. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002; 102: 152-8
20. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 622-35
21. Franceschi S, Munoz N, Bosch XF, et al. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996; 5: 567-75
22. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 Suppl. 1: S7-15
23. Bernard HU. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir Ther 2002; 7: 219-37
24. Yang L, Mohr I, Fouts E, et al. The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase. Proc Natl Acad Sci U S A 1993; 90: 5086-90
25. Mohr IJ, Clark R, Sun S, et al. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 1990; 250: 1694-9
26. Giri I, Yaniv M. Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J 1988; 7: 2823-9
27. Thain A, Webster K, Emery D, et al. DNA binding and bending by the human papillomavirus type 16 E2 protein: recognition of an extended binding site. J Biol Chem 1997; 272: 8236-42
28. You J, Croyle JL, Nishimura A, et al. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-60
29. Bastien N, McBride AA. Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology 2000; 270: 124-34
30. Stubenrauch F, Zobel T, Iftner T. The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31. J Virol 2001; 75: 4139-49
31. Stubenrauch F, Hummel M, Iftner T, et al. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J Virol 2000; 74: 1178-86
32. Doorbar J, Ely S, Sterling J, et al. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991; 352: 824-7
33. Straight SW, Hinkle PM, Jewers RJ, et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993; 67: 4521-32
34. Genther SM, Sterling S, Duensing S, et al. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol 2003; 77: 2832-42
35. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9
36. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10: 4129-35
37. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36
38. Jones DL, Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997; 71: 2905-12
39. Slebos RJ, Lee MH, Plunkett BS, et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1994; 91: 5320-4
40. Butz K, Geisen C, Ullmann A, et al. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 1996; 68: 506-13
41. Wrede D, Tidy JA, Crook T, et al. Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog 1991; 4: 171-5
42. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6: 873-5
43. Mantovani F, Massimi P, Banks L. Proteasome-mediated regulation of the hDlg tumour suppressor protein. J Cell Sci 2001; 114: 4285-92
44. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998; 17: 2943-54
45. Grm HS, Massimi P, Gammoh N, et al. Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene 2005; 24: 5149-64
46. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7
47. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-4
48. Chellappan S, Kraus VB, Kroger B, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 1992; 89: 4549-53
49. Flores ER, len-Hoffmann BL, Lee D, et al. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000; 74: 6622-31
50. Jones DL, Thompson DA, Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997; 239: 97-107
51. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990; 64: 723-30
52. Munger K, Yee CL, Phelps WC, et al. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J Virol 1991; 65: 3943-8
53. Munger K, Werness BA, Dyson N, et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-105
54. Massimi P, Pim D, Storey A, et al. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996; 12: 2325-30
55. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999; 259: 305-13
56. Mannhardt B, Weinzimer SA, Wagner M, et al. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol 2000; 20: 6483-95
57. Gammoh N, Grm HS, Massimi P, et al. Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol 2006; 80: 1787-97
58. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65: 606-12
59. Lehn H, Villa LL, Marziona F, et al. Physical state and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract. J Gen Virol 1988; 69 (Pt 1): 187-96
60. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002; 40: 886-91
61. Schneider-Maunoury S, Croissant O, Orth G. Integration of human papillomavirus type 16 DNA sequences: a possible early event in the progression of genital tumors. J Virol 1987; 61: 3295-8
62. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995; 69: 2989-97
63. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 1995; 92: 1654-8
64. Kalantari M, Blennow E, Hagmar B, et al. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol Pathol 2001; 10: 46-54
65. Thorland EC, Myers SL, Gostout BS, et al. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 2003; 22: 1225-37
66. Thorland EC, Myers SL, Persing DH, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res 2000; 60: 5916-21
67. Kalantari M, Karlsen F, Kristensen G, et al. Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 1998; 17: 146-53
68. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005; 32 Suppl. 1: S72-81
69. Flores ER, Allen-Hoffmann BL, Lee D, et al. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 1999; 262: 344-54
70. Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22: 3004-7
71. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27
72. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55
73. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65
74. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8
75. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001; 19: 2549-56
76. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-7
77. Li J, Sun Y, Garen A. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci U S A 2002; 99: 16232-6
78. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11: 1011-8
79. Tindle RW, Fernando GJ, Sterling JC, et al. A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991; 88: 5887-91
80. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154: 5934-43
81. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9
82. Osen W, Peiler T, Ohlschlager P, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001; 19: 4276-86
83. Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-40
84. Michel N, Osen W, Gissmann L, et al. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002; 294: 47-59
85. Kasukawa H, Howley PM, Benson JD. A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro. J Virol 1998; 72: 8166-73
86. Hall AH, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066-9
87. von Knebel Doeberitz M, Rittmuller C, zur Hausen H, et al. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992; 51: 831-4
88. Shillitoe EJ. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther 2006; 13: 445-50
89. Hwang ES, Riese DJ, Settleman J, et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 1993; 67: 3720-9
90. Goodwin EC, Naeger LK, Breiding DE, et al. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol 1998; 72: 3925-34
91. Sanchez-Perez AM, Soriano S, Clarke AR, et al. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. J Gen Virol 1997; 78 (Pt 11): 3009-18
92. Desaintes C, Demeret C, Goyat S, et al. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997; 16: 504-14
93. Davidson EJ, Brown MD, Burt DJ, et al. Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells. Int J Cancer 2001; 94: 807-12
94. Maitland NJ, Conway S, Wilkinson NS, et al. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J Pathol 1998; 186: 275-80
95. de Jong A, van der Burg SH, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-9
96. Bontkes HJ, de Gruijl TD, Bijl A, et al. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 1999; 80 (Pt 9): 2453-9
97. Brandsma JL, Shlyankevich M, Zhang L, et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol 2004; 78: 116-23
98. Qian J, Dong Y, Pang YY, et al. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006; 118: 3022-9
99. Hwang ES, Naeger LK, DiMaio D. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene 1996; 12: 795-803
100. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995; 69: 7791-9
101. Demeret C, Desaintes C, Yaniv M, et al. Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. J Virol 1997; 71: 9343-9
102. Thierry F, Howley PM. Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol 1991; 3: 90-100
103. Wells SI, Aronow BJ, Wise TM, et al. Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells. Proc Natl Acad Sci U S A 2003; 100: 7093-8
104. Wells SI, Francis DA, Karpova AY, et al. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J 2000; 19: 5762-71
105. Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 2000; 74: 2679-86
106. Webster K, Parish J, Pandya M, et al. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000; 275: 87-94
107. Demeret C, Garcia-Carranca A, Thierry F. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 2003; 22: 168-75
108. Frattini MG, Hurst SD, Lim HB, et al. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J 1997; 16: 318-31
109. Desaintes C, Goyat S, Garbay S, et al. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 1999; 18: 4538-45
110. Parish J, Kowalczyk AM, Chen H, et al. E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J Virol 2006; 80: 4580-90
111. Massimi P, Pim D, Bertoli C, et al. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 1999; 18: 7748-54
112. Valdez GV, Sutter G, Jose MV, et al. Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000; 88: 1650-62
113. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13: 592-7
114. Bechtold V, Beard P, Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 2003; 77: 2021-8
115. Green KL, Southgate TD, Mulryan K, et al. Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther 2006; 17: 147-57
116. Parton A, Grand RJ, Biggs P, et al. Integrated HPV 1 genomes in a human keratinocyte cell line can be transactivated by a SV40/BPV1 recombinant virus which expresses BPV1 E2 proteins. Virology 1990; 175: 508-17
117. Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-50
118. DeMatteo RP, Raper SE, Ahn M, et al. Gene transfer to the thymus: a means of abrogating the immune response to recombinant adenovirus. Ann Surg 1995; 222: 229-39
119. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 1993; 90: 11307-11
120. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39-46
121. Han R, Reed CA, Cladel NM, et al. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 2000; 18: 2937-44
122. Deshayes S, Morris MC, Divita G, et al. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49
123. Roeder GE, Parish JL, Stern PL, et al. Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol Appl Biochem 2004; 40: 157-65
124. Elliott GD, Meredith DM. The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J Gen Virol 1992; 73 (Pt 3): 723-6
125. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33
126. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 1999; 6: 149-51
127. Roy I, Holle L, Song W, et al. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res 2002; 22: 3185-9
128. Zender L, Kuhnel F, Kock R, et al. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002; 9: 489-96
129. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-3
130. Qiu Z, Harms JS, Zhu J, et al. Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 2004; 78: 4224-33
131. Kong B, Wang W, Liu C, et al. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo 2003; 17: 153-6
132. Brewis ND, Phelan A, Normand N, et al. Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis. Mol Ther 2003; 7: 262-70
133. Hung CF, He L, Juang J, et al. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002; 76: 2676-82
134. Fang B, Xu B, Koch P, et al. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther 1998; 5: 1420-4
135. Falnes PO, Wesche J, Olsnes S. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 2001; 40: 4349-58
136. Lundberg M, Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol 2001; 19: 713-4
137. Elliott G, O'Hare P. Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J Virol 1999; 73: 4110-9
138. Wybranietz WA, Prinz F, Spiegel M, et al. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1999; 1: 265-74
139. Weiner AL. Liposomes for protein delivery: selecting manufacture and development processes. Immunomethods 1994; 4: 201-9
140. Peppas NA, Bures P, Leobandung W, et al. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50: 27-46
141. Lu D, Hickey AJ. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech 2005; 6 (4): E641-8
142. Webster K, Taylor A, Gaston K. Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. J Gen Virol 2001; 82: 201-13